Current Report Filing (8-k)
June 07 2021 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): June
1, 2021
SILO PHARMA, INC.
(Name of registrant in its charter)
Delaware
|
|
000-54872
|
|
27-3046338
|
(State or jurisdiction of
|
|
(Commission File
|
|
(IRS Employer
|
incorporation or organization)
|
|
Number)
|
|
Identification No.)
|
560 Sylvan Ave, Suite 3160
Englewood Cliffs NJ 07632
(Address of principal executive offices)
(718) 400-9031
(Registrant’s telephone number)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General
Instructions A.2 below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act: None.
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive
Agreement.
On June 1, 2021 (the “Effective Date”),
Silo Pharma, Inc. (the “Company”) entered into a sponsored research agreement (the “Agreement”) with The Regents
of the University of California, on behalf of its San Francisco Campus (“UCSF”) pursuant to which UCSF shall conduct a study
to examine psilocybin’s effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for
Parkinson’s Disease, chronic pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a fee in the mid
six digit figures to conduct the research. The Agreement shall be effective for a period of two years from the Effective Date, subject
to renewal or earlier termination as set forth in the Agreement.
The foregoing
summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement which is
filed as Exhibit 10.1 to this Current Report on Form 8-K and is hereby incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibits
|
#
|
Pursuant to Item 601(b)(10)
of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because
the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SILO PHARMA, INC.
|
|
|
|
Date: June 7, 2021
|
By:
|
/s/ Eric Weisblum
|
|
|
Eric Weisblum,
Chief Executive Officer
|
-2-